Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gallbladder Cancer: early-phase trial registry
3 of 12 indexed Gallbladder Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 3 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Gallbladder Cancer: 12 US clinical trials tracked, 3 recruiting.
Gallbladder Cancer is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Lisata Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition gallbladder-cancer
OPEN 3 | RECR 25% | LATE 0 | EARLY 7 | RANK #1429 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Gallbladder Cancer lists 3 open slots (25% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gallbladder Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gallbladder Cancer is recruiting below its size-band peers.
3 of 12 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gallbladder Cancer trials is spread across many organizations.
Lisata Therapeutics accounts for 1 of 12 trials (8.3%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Gallbladder Cancer enrolment sits around 67 participants.
Median target enrolment is 67 among the 11 trials that report a genuine target (sentinel values excluded). 6 of those (54.5%) plan for fewer than 100 participants.
-
Gallbladder Cancer research is mostly interventional.
10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
University of California, Davis
NCT06101277
DESTINY-PANTUMOUR04
AstraZeneca
NCT07124000
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
NCT07146646
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Compass Therapeutics
NCT05506943
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Lisata Therapeutics
NCT05712356
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
NCT02293954
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
University of Pittsburgh
NCT01640522
Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder
Wake Forest University Health Sciences
NCT00489515
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Vanderbilt-Ingram Cancer Center
NCT00987766
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
University of Chicago
NCT00003557
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
Memorial Sloan Kettering Cancer Center
NCT00003923
DX-8951f in Treating Patients With Biliary Cancer
Daiichi Sankyo
NCT00005938
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Gallbladder Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gallbladder Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gallbladder Cancer page
12 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Gallbladder Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Lisata Therapeutics sponsors the most Gallbladder Cancer trials on record, review their full trial history before evaluating a specific study. See Lisata Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gallbladder Cancer condition card totals 12 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.